VCD Medical Wins FDA 510(k) Clearance for Its VEnice Vein Closure Device

VCD Medical, a medical technology company based in Brescia, Italy, announced on September 29 that its VEnice vein closure system received 510(k) clearance from the U.S. Food and Drug Administration. The device is a vascular clip technology intended to close superficial and perforator veins through a percutaneous approach, meaning doctors place the implant through a small puncture rather than making an incision.

The system is designed for varicose vein treatment in an outpatient, office-based setting. VCD Medical positions VEnice as a fast and simple closure option that improves patient comfort immediately after the procedure and supports workflow efficiency in the clinic. The FDA's public device database lists the cleared device under 510(k) number K260677 as a Vessel Closure Device.

The clearance is a commercial milestone for a small company entering the U.S. market. Chief executive Francesco Piccagli called it a significant step in the company's U.S. commercialization plans, while U.S. general manager Denna Babul said the focus now shifts to education and hands-on experience for the vascular community.

A note on what this is and is not: 510(k) clearance means the FDA reviewed the device and found it substantially equivalent to an existing legally marketed device. It is a regulatory clearance, not evidence of clinical superiority, and the device has yet to be adopted at scale in U.S. practice. Availability for physicians will depend on the company's commercial rollout.

Why it matters: chronic venous disease and varicose veins are among the most common vascular conditions, and current closure options such as laser ablation, radiofrequency, adhesive, and foam sclerotherapy each carry tradeoffs in comfort, recurrence, and procedure time. A clip-based percutaneous alternative gives physicians another option, and office-based viability matters for cost and access.